Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,640 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma).
Chae YK, Othus M, Patel SP, Gerber DE, Tanvetyanon T, Kim HS, Chung LI, McLeod CM, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. Chae YK, et al. Among authors: chung li. Ther Adv Med Oncol. 2024 Nov 22;16:17588359241293401. doi: 10.1177/17588359241293401. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39583952 Free PMC article.
Polygenic risk score and lung adenocarcinoma risk among never-smokers by EGFR mutation status-a brief report.
Blechter B, Hsiung CA, Wang X, Zhang H, Seow WJ, Shi J, Chatterjee N, Kim HN, Wong MP, Hong YC, Wong JY, Dai J, Hosgood HD, Wang Z, Chang IS, Choi J, Wang J, Song M, Hu W, Zheng W, Kim JH, Zhou B, Albanes D, Shin MH, Chung LP, An SJ, Zheng H, Yatabe Y, Zhang XC, Kim YT, Shu XO, Kim YC, Vermeulen RCH, Bassig BA, Chang J, Man Ho JC, Ji BT, Kubo M, Daigo Y, Momozawa Y, Kamatani Y, Honda T, Kunitoh H, Watanabe SI, Miyagi Y, Nakayama H, Matsumoto S, Tsuboi M, Goto K, Yin Z, Takahashi A, Goto A, Minamiya Y, Shimizu K, Tanaka K, Wu T, Wei F, Su J, Kim YH, Oh IJ, Fun Lee VH, Su WC, Chen YM, Chang GC, Chen KY, Huang MS, Lin HC, Seow A, Park JY, Kweon SS, Chen CJ, Gao YT, Wu C, Qian B, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Tsai YH, Jung YJ, Guo H, Hu Z, Chen TY, Burdett L, Yeager M, Hutchinson A, Berndt SI, Wu W, Wang J, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Chen CH, Xu J, Guan P, Tan W, Wang CL, Loon Sihoe AD, Chen Y, Choi YY, Kim JS, Yoon HI, Cai Q, Park IK, Xu P, He Q, Chen CY, Wu J, Lim WY, Chen KC, Chan JKC, Li J, Chen H, Yu CJ, Jin L, Fraumeni JF Jr, Liu J, Landi MT, Yamaji T, Yang Y, Hicks B, Wyatt K, Li SA, Ma H, Song B, Wang Z, Cheng S, Li X, Ren Y, Iwasaki M, Zhu J,… See abstract for full author list ➔ Blechter B, et al. Among authors: chung lp. J Thorac Oncol. 2024 Nov 22:S1556-0864(24)02482-1. doi: 10.1016/j.jtho.2024.11.019. Online ahead of print. J Thorac Oncol. 2024. PMID: 39581378
Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.
Sheth KN, Albers GW, Saver JL, Campbell BCV, Molyneaux BJ, Hinson HE, Cordonnier C, Steiner T, Toyoda K, Wintermark M, Littauer R, Collins J, Lucas N, Nogueira RG, Simard JM, Wald M, Dawson K, Kimberly WT; CHARM Trial investigators. Sheth KN, et al. Lancet Neurol. 2024 Dec;23(12):1205-1213. doi: 10.1016/S1474-4422(24)00425-3. Lancet Neurol. 2024. PMID: 39577921 Clinical Trial.
Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors.
Taylor MH, Naing A, Powderly J, Woodard P, Chung L, Lin WH, Tian H, Siemers N, Xiang H, Deng R, Hong K, Valencia D, Huang T, Zhu Y, Liao XC, Schebye XM, Patel MR. Taylor MH, et al. Among authors: chung l. J Immunother Cancer. 2024 Nov 20;12(11):e010006. doi: 10.1136/jitc-2024-010006. J Immunother Cancer. 2024. PMID: 39567210 Free PMC article. Clinical Trial.
1,640 results